| 1.25 0.09 (7.76%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.69 |
1-year : | 1.97 |
| Resists | First : | 1.45 |
Second : | 1.69 |
| Pivot price | 1.19  |
|||
| Supports | First : | 1.19 |
Second : | 1.03 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.21 |
| MA(100) : | 1.31 |
MA(250) : | 1.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46.5 |
D(3) : | 28.2 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 4.21 | Low : | 1.03 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GERN ] has closed below upper band by 31.8%. Bollinger Bands are 17.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.26 | 1.26 - 1.27 |
| Low: | 1.13 - 1.14 | 1.14 - 1.14 |
| Close: | 1.24 - 1.25 | 1.25 - 1.26 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Fri, 07 Nov 2025
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help (GERN) - Seeking Alpha
Thu, 06 Nov 2025
Geron Corporation (NASDAQ:GERN) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 06 Nov 2025
Geron Corporation’s Q3 2025 Financial Performance and Strategic Progress - The Globe and Mail
Wed, 05 Nov 2025
Geron (GERN) Revenue Growth Forecast at 39.2% Per Year Challenges Market Narrative Heading Into Earnings - Sahm
Wed, 05 Nov 2025
Geron Corporation (GERN) Q3 2025 Earnings Highlight RYTELO Devel - GuruFocus
Wed, 05 Nov 2025
Geron Corp (GERN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst RYTELO Demand Challenges - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 638 (M) |
| Held by Insiders | 5.3406e+008 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 92,130 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.699e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -53.6 % |
| Operating Margin | -25.4 % |
| Return on Assets (ttm) | -9.7 % |
| Return on Equity (ttm) | -31.1 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 806.31 |
| Sales Per Share | 2.88509e+008 |
| EBITDA (p.s.) | 1.4107e+008 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -178 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.73 |
| Dividend | 0 |
| Forward Dividend | 8.692e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|